Global Osteomyelitis Drugs Market, By Disease Type (Acute Osteomyelitis, Chronic Osteomyelitis, Vertebral Osteomyelitis), Diagnosis (Blood Test, Imaging Test, Bone Biopsy, Others), Treatment (Surgery, Medication, Others), Route of Administration (Oral, Parenteral, Topical, Others), End-Users (Hospitals, Specialty Clinics, Home Healthcare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) – Industry Trends and Forecast to 2029.
Global Osteomyelitis Drugs Market Analysis and Size
The occurrence of osteomyelitis has risen in recent years, creating good conditions for the industry to expand. According to the National Center for Biotechnology Information, the global annual occurrence rate of osteomyelitis was 13 per 100,000 in 2016. Because of the rising occurrence of osteomyelitis, there will be a surge in demand for therapies, propelling the worldwide osteomyelitis market forward. This further heightened the demand of osteomyelitis drugs in the market.
- Data Bridge Market Research analyses that the osteomyelitis drugs market was valued at USD 1.34 billion in 2021 and is expected to reach USD 2.29 billion by 2029, registering a CAGR of 6.90% during the forecast period of 2022 to 2029. The market report curated by the Data Bridge Market Research team includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Global Osteomyelitis Drugs Market Definition
Bacteria or fungus cause osteomyelitis, which is a bone infection. Swelling from this painful bone infection can damage bone and lead to bone loss. Antibiotics are often effective when used quickly. Surgery may be required to drain abscesses or remove damaged bone in some persons. Osteomyelitis is more common in young children, the elderly, and persons with diabetes.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2019 - 2014)
|
|
Quantitative Units
|
Revenue in USD Billion, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Disease Type (Acute Osteomyelitis, Chronic Osteomyelitis, Vertebral Osteomyelitis), Diagnosis (Blood Test, Imaging Test, Bone Biopsy, Others), Treatment (Surgery, Medication, Others), Route of Administration (Oral, Parenteral, Topical, Others), End-Users (Hospitals, Specialty Clinics, Home Healthcare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Johnson & Johnson Private Limited (US), Mylan N.V. (US), Teva Pharmaceutical Industries Ltd.(Jerusalem), Sanofi (France), Pfizer Inc. (US), GlaxoSmithKline plc (UK), AbbVie Inc. (US), Novartis AG (Switzerland), Eli Lilly and Company (US), F. Hoffmann-La Roche Ltd. (Switzerland), Merck & Co., Inc. (US), AstraZeneca (UK), Abbott (US), Sun Pharmaceutical Industries Ltd. (Mumbai), Aurobindo Pharma (Hyderabad), Lupin (Mumbai), Nabriva Therapeutics plc. (Ireland), Vyome Therapeutics Inc. (Delhi), Debiopharm (Switzerland), Otsuka Pharmaceutical Co., Ltd. (Japan)
|
|
Market Opportunities
|
|
Osteomyelitis Drugs Market Dynamics
Drivers
-
Increasing Prevalence of Chronic Diseases
The osteomyelitis drugs market is driven by an increase in prevalence of chronic diseases. Osteomyelitis is more common in persons who have chronic health problems including diabetes or kidney failure. If a person has diabetes and has foot ulcers, they may get osteomyelitis.
-
Increasing Investment for Healthcare Infrastructure
Another significant factor influencing the growth rate of osteomyelitis drugs market is the rising healthcare expenditure which helps in improving its infrastructure.
Furthermore, rising initiatives by public and private organizations to spread awareness will expand the osteomyelitis drugs market. Additionally, high disposable income and rising number of geriatric populations will result in the expansion of osteomyelitis drugs market. Along with this, favourable government policies and rising incidences of smoking will enhance the growth rate of the market.
Opportunities
- Increase in the number of research and development activities
Moreover, the market's growth is fueled by an increase in the number of research and development activities. This will provide beneficial opportunities for the osteomyelitis drugs market growth. Along with this, rising drug approvals and launches will further propel the market’s growth rate.
Moreover, rising investment for the development of advanced technologies and increase in the number of emerging markets will further provide beneficial opportunities for the osteomyelitis drugs market growth during the forecast period.
Restraints/Challenges Global Osteomyelitis Drugs Market
- Medical reimbursement for osteomyelitis
Medical reimbursement for osteomyelitis is a major stumbling block. Medical reimbursement is one of the most important factors determining the acceptance and demand of particular diagnostic and therapeutic items among health care professionals and patients at the national level. Many private insurance companies do not cover or reimburse osteomyelitis surgeries.
On the other hand, the high cost associated with the treatment and osteomyelitis drugs will obstruct the growth rate of market. The dearth of skilled professionals and lack of healthcare infrastructure in developing economies will challenge the osteomyelitis drugs market. Additionally, impact of COVID-19 on supply chain and the dearth of awareness will act as restrain and further impede the growth rate of market during the forecast period of 2022-2029.
This osteomyelitis drugs market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the osteomyelitis drugs market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Patient Epidemiology Analysis
The overall incidence of osteomyelitis in the United States is unknown, however reports suggest that it affects as many as 1 in 675 hospital admissions in the United States each year, or approximately 50,000 cases. According to other studies, there are 21.8 instances of osteomyelitis per 100,000 person-years. For unexplained reasons, the frequency was higher in men, although it rises with age, owing to an increase in the prevalence of comorbid conditions such as diabetes and peripheral vascular disease.
Osteomyelitis drugs market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
COVID-19 Impact on Osteomyelitis Drugs Market
Since its emergence in December 2019, the COVID-19 virus has spread to nearly every country on the planet, prompting the World Health Organization (WHO) to declare it a public health emergency. This can be ascribed to severe disruptions in their respective manufacturing and supply-chain operations therefore as consequence of multiple precautionary lockdowns and other limitations imposed by governments all over the world. The osteomyelitis drugs market is no exception. Furthermore, consumer preferences has decreased as people are now much more concentrated on removing non-essential expenses from their budgets as the wider economic situation of most people has been adversely impacted by this outbreak. Over the forecast period, the aforementioned factors are likely to have a negative impact on the osteomyelitis drugs market's revenue trajectory.
Recent Development
- In January 2021, Locate Bio, has been awarded Food and Drug Administration (FDA) breakthrough device designation for CognitOss. Surgical debridement, long-term, high-dose antibiotic therapy, and – for larger lesions – bone grafting, which typically necessitates a second surgical surgery to remove the non-resorbable bone graft, are currently the primary treatments for chronic osteomyelitis.
Global Osteomyelitis Drugs Market Scope
The osteomyelitis drugs market is segmented on the basis of disease type, treatment, diagnosis, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Disease Type
- Acute Osteomyelitis
- Chronic Osteomyelitis
- Vertebral Osteomyelitis
On the basis of disease type, the osteomyelitis drugs market is segmented into acute osteomyelitis, chronic osteomyelitis, and vertebral osteomyelitis.
Treatment
- Medication
- Surgery
- Others
On the basis of treatment, the osteomyelitis drugs market is segmented into medication, surgery and others. Medication segment is further segmented into antibiotics, antifungals, nonsteroidal anti-inflammatory drugs (NSAIDs) and others.
Diagnosis
- Blood Test
- Imaging Test
- Bone Biopsy
- Others
On the basis of diagnosis, the osteomyelitis drugs market is segmented into blood test, imaging test, bone biopsy, and others. Imaging test further segmented into X-rays, MRI, CT scan and others.
Route of Administration
- Oral
- Parenteral
- Topical
- Others
Route of administration segment of osteomyelitis drugs market is segmented into oral, parenteral, topical and others.
End-Users
- Hospitals
- Specialty Clinics
- Home Healthcare
- Others
On the basis of end-users, the osteomyelitis drugs market is segmented into hospitals, specialty clinics, home healthcare and others.
Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Others
On the basis of distribution channel, the osteomyelitis drugs market has also been segmented into hospital pharmacy, retail pharmacy, and others
Osteomyelitis Drugs Market Regional Analysis/Insights
The osteomyelitis drugs market is analysed and market size insights and trends are provided by country, type, treatment, diagnosis, route of administration, end-users and distribution channel as referenced above.
The countries covered in the osteomyelitis drugs market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
North America dominates the osteomyelitis drugs market because of the advancement in technology and growing prevalence of infectious diseases in this region. Additionally, the presence of major key players will enhance the market’s growth rate in this region.
Asia-Pacific is expected to grow during the forecast period due to rising number of joint replacement surgeries and swiftly improving healthcare infrastructure in this region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Osteomyelitis Drugs Market Share Analysis
The Osteomyelitis drugs market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to osteomyelitis drugs market.
Some of the major players operating in the osteomyelitis drugs market are
- Johnson & Johnson Private Limited (US)
- Mylan N.V. (US)
- Teva Pharmaceutical Industries Ltd.(Jerusalem)
- Sanofi (France)
- Pfizer Inc. (US)
- GlaxoSmithKline plc (UK)
- AbbVie Inc. (US)
- Novartis AG (Switzerland)
- Eli Lilly and Company (US)
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Merck & Co., Inc. (US)
- Otsuka Pharmaceutical Co., Ltd. (Japan)
- AstraZeneca (UK)
- Abbott (US)
- Sun Pharmaceutical Industries Ltd. (Mumbai)
- Aurobindo Pharma (Hyderabad)
- Lupin (Mumbai)
- Nabriva Therapeutics plc. (Ireland)
- Vyome Therapeutics Inc. (Delhi)
- Debiopharm (Switzerland)
SKU-